3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Thrombocytopenia
3
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Leukemia, Myeloid, Acute
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Interventions
fludarabine phosphate
34
Cyclophosphamide
34
Peripheral Blood Stem Cell Transplantation
23
Busulfan
22
Mycophenolic Acid
21
Cyclosporine
20
Whole-Body Irradiation
19
Tacrolimus
18
Antilymphocyte Serum
18
Melphalan
16
Filgrastim
16
Radiotherapy
15
Methotrexate
14
fludarabine
12
Cord Blood Stem Cell Transplantation
12
Methylprednisolone
10
Cytarabine
10
Etoposide
8
sargramostim
6
Granulocyte Colony-Stimulating Factor
5
Cyclosporins
5
Alemtuzumab
4
thymoglobulin
3
merphos
3
Tretinoin
3
Thiotepa
3
Thalidomide
3
Sirolimus
3
Rituximab
3
Leucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tranexamic Acid
×
Classical hematology
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled